This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected\ncurrently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates\nchosen to provide an extreme challenge for antibacterial activity. FEPâ??ZID had a very broad\nand potent in vitro spectrum of activity, and was highly active against many MDR isolates of\nEnterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. Notably, it inhibited isolates\nproducing carbapenemases of Ambler classes A, B, and D, and P. aeruginosa isolates with multiple\nresistance mechanisms including combinations of upregulated efflux, diminished or non-functional\nOprD porins, and AmpC overproduction. Its clinical role will be determined initially by the\nbreakpoints assigned to it, comparison studies with other investigational Beta-lactamase inhibitor\ncombinations, and ultimately by the developing body of therapeutic outcome data.
Loading....